# Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/noncirrhotic-nonalcoholic-steatohepatitis-with-liver-fibrosis-developing-drugs-for-treatment/557c8137-5d47-4a52-ab3f-6fd88febd924

> FDA guidance document: Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment. Issue date: December 04, 2018. Get complete insights and analysis.

---

## Details

- Title: Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2018-12-04
- Comment Close Date: 2019-02-04
- Last Changed: 2020-05-14
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-3632">FDA-2018-D-3632</a>

## Related Documents

- [Erosive Esophagitis: Developing Drugs for Treatment: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/erosive-esophagitis-developing-drugs-for-treatment-draft-guidance-for-industry/db47ebb5-eadc-4f7b-a236-ac6b016c3ec7)
- [Erosive Esophagitis: Developing Drugs for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/erosive-esophagitis-developing-drugs-for-treatment/985e94e3-4616-49e9-822e-0854256bb10e)
- [Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/nonalcoholic-steatohepatitis-with-compensated-cirrhosis-developing-drugs-for-treatment-guidance-for-industry/71c114f5-4930-4cda-87ef-12936678931f)